Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.54 |
| ▸ | SI | P14410 | 1/20 | 0.54 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171122 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL472723 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL1903946 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138462 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138705 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138882 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138788 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL3442509 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138989 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 | |
| SCHEMBL6138757 | 1.00 | HAO1 (0.55) | HAO1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109716491-B | Method for manufacturing field effect transistor and method for manufacturing wireless communication device | 东丽株式会社 | 2023-06-09 | — | — | CN | disclosed |
| CN-116120173-A | Synthesis method of long-chain alkyl-beta-keto ester compound | 金浦新材料股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3514822-B1 | METHOD FOR MANUFACTURING FIELD EFFECT TRANSISTOR AND METHOD FOR MANUFACTURING WIRELESS COMMUNICATION DEVICE | TORAY INDUSTRIES (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-11094899-B2 | Method for manufacturing field effect transistor and method for manufacturing wireless communication device | TORAY INDUSTRIES, INC. | 2021-08-17 | — | — | US | disclosed |
| EP-3367402-B1 | CAPACITOR, METHOD FOR MANUFACTURING SAME, AND WIRELESS COMMUNICATION DEVICE USING SAME | TORAY INDUSTRIES (JP) | 2021-07-07 | — | — | EP | disclosed |
| CN-107431096-B | Rectifier element, method for manufacturing the same, and wireless communication device | 东丽株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-10636866-B2 | Capacitor, method for manufacturing same, and wireless communication device using same | TORAY INDUSTRIES, INC. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-10490748-B2 | Rectifying element, method for producing same, and wireless communication device | TORAY INDUSTRIES, INC. (JP) | 2019-11-26 | — | — | US | disclosed |
| EP-3514822-A1 | METHOD FOR MANUFACTURING FIELD EFFECT TRANSISTOR AND METHOD FOR MANUFACTURING WIRELESS COMMUNICATION DEVICE | Toray Industries, Inc. (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190198786-A1 | METHOD FOR MANUFACTURING FIELD EFFECT TRANSISTOR AND METHOD FOR MANUFACTURING WIRELESS COMMUNICATION DEVICE | TORAY INDUSTRIES, INC. (JP) | 2019-06-27 | — | — | US | disclosed |
| US-6713059-B2 | CARRIER MOLECULE COUPLED TO AN AUTOINDUCER OF A GRAM NEGATIVE BACTERIA; E.G., N-(3-OXODODECANOYL)-L-HOMOSERINE LACTONE, N-(BUTANOYL)-L-HOMOSERINE LACTONE, OR N-HEXANOYL-HOMOSERINE LACTONE | UNIVERSITY OF ROCHESTER | 2004-03-30 | — | — | US | disclosed |
| WO-2004016213-A2 | COMBINATORIAL LIBRARIES OF AUTOINDUCER ANALOGS, AUTOINDUCER AGONISTS AND ANTAGONISTS, AND METHODS OF USE THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-02-26 | — | — | WO | disclosed |
| US-20030095985-A1 | Immunogenic conjugates of Gram-negative bacterial autoinducer molecules and antibodies raised against the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-22 | — | — | US | disclosed |
| US-6492545-B2 | Process for producing optically active alcohol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-12-10 | — | — | US | disclosed |
| US-6395282-B1 | CARRIER MOLECULE CONJUGATED TO SPECIFIC AUTOINDUCERS; VACCINES FOR THE TREATMENT AND PREVENTION OF INFECTION | UNIVERSITY OF ROCHESTER | 2002-05-28 | — | — | US | disclosed |
| US-20020035283-A1 | Process for producing optically active alcohol | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1176135-A1 | Process for producing optically active alcohol | Takasago International Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| US-6057288-A | N-(3-OXODODECANOYL)HOMOSERINE LACTONE, USEFUL FOR TREATING OR PREVENTING INFECTION BY PSEUDOMONAS AERUGINOSA | UNIVERSITY OF IOWA (US) | 2000-05-02 | — | — | US | disclosed |
| US-5591872-A | REGULATION OF GENE EXPRESSION IN PSEUDOMONAS, TREATMENT OF INFECTION | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1997-01-07 | — | — | US | disclosed |
| US-4181736-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | LABORATOIRES JACQUES LOGEAIS (FR) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095985-A1 | Immunogenic conjugates of Gram-negative bacterial autoinducer molecules and antibodies raised against the same | PGLS, LRBA, ANTXR2 | HAO1 3077/4885GAA 2243/4885MGAM 119/4885 |
| US-20020035283-A1 | Process for producing optically active alcohol | ADH1A, ADH5, ADH1C | HAO1 546/4885GAA 1962/4885MGAM 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.